- Home
- CVKD vs MTR Comparison
CVKD vs MTR Comparison
Compare CVKD & MTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CVKD | MTR |
|---|---|---|
| Founded | 2022 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 5.8M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | CVKD | MTR |
|---|---|---|
| Price | $1.90 | $2.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 53.0K | 3.4K |
| Earning Date | 05-08-2026 | 03-31-2026 |
| Dividend Yield | N/A | ★ 4.82% |
| EPS Growth | ★ 23.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $22.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.86 | $2.84 |
| 52 Week High | $14.64 | $5.94 |
Technical Indicators
Market Signals| Indicator | CVKD | MTR |
|---|---|---|
| Relative Strength Index (RSI) | 29.53 | 28.70 |
| Support Level | $1.86 | N/A |
| Resistance Level | $3.89 | $4.99 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 1.90 | 7.41 |
Price Performance
Historical ComparisonAbout CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
About MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.